Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner

International Immunopharmacology

Volumn 51, Issue , 2017, Pages 47-56

  Lee, Changhyun ^a,b   Kim, Byeong Gwan ^c   Kim, Jee Hyun ^a,c   Chun, Jaeyoung ^a   Im, Jong Pil ^a   Kim, Joo Sung ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

Author keywords

Butyrates; Histone deactylase inhibitors; Inflammatory bowel diseases; Mice; NF kappa B

Indexed keywords

BUTYRIC ACID; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; PIROXICAM; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; HISTONE DEACETYLASE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOKINE PRODUCTION; DEACETYLATION; DNA BINDING; EXPERIMENTAL COLITIS; FLUID INTAKE; HISTONE ACETYLATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; WEIGHT CHANGE; ANIMAL; C57BL MOUSE; COLITIS; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTYRIC ACID; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASES; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; RAW 264.7 CELLS; SIGNAL TRANSDUCTION;

EID: 85026922078     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.07.023     Document Type: Article

References (44)

1. Ng, W.K., Wong, S.H., Ng, S.C., Changing epidemiological trends of inflammatory bowel disease in Asia. Intestinal Research 14:2 (2016), 111–119.
2. Kaplan, G.G., Ng, S.C., Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology, 152(2), 2017, 313-321.e2.
3. Hou, J.K., Abraham, B., El-Serag, H., Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 106:4 (2011), 563–573.
4. Amre, D.K., D'Souza, S., Morgan, K., Seidman, G., Lambrette, P., Grimard, G., Israel, D., Mack, D., Ghadirian, P., Deslandres, C., Chotard, V., Budai, B., Law, L., Levy, E., Seidman, E.G., Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 102:9 (2007), 2016–2025.
5. Liu, X., Wu, Y., Li, F., Zhang, D., Dietary fiber intake reduces risk of inflammatory bowel disease: result from a meta-analysis. Nutrition Research (New York, N.Y.) 35:9 (2015), 753–758.
6. Ananthakrishnan, A.N., Khalili, H., Konijeti, G.G., Higuchi, L.M., de Silva, P., Korzenik, J.R., Fuchs, C.S., Willett, W.C., Richter, J.M., Chan, A.T., A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 145:5 (2013), 970–977.
7. Hamer, H.M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F.J., Brummer, R.J., Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 27:2 (2008), 104–119.
8. Liu, J., Wang, F., Luo, H., Liu, A., Li, K., Li, C., Jiang, Y., Protective effect of butyrate against ethanol-induced gastric ulcers in mice by promoting the anti-inflammatory, anti-oxidant and mucosal defense mechanisms. Int. Immunopharmacol. 30 (2016), 179–187.
9. Yin, L., Laevsky, G., Giardina, C., Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 276:48 (2001), 44641–44646.
10. Place, R.F., Noonan, E.J., Giardina, C., HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol. 70:3 (2005), 394–406.
11. Park, J.S., Lee, E.J., Lee, J.C., Kim, W.K., Kim, H.S., Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int. Immunopharmacol. 7:1 (2007), 70–77.
12. Krokowicz, L., Stojcev, Z., Kaczmarek, B.F., Kociemba, W., Kaczmarek, E., Walkowiak, J., Krokowicz, P., Drews, M., Banasiewicz, T., Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study. Int. J. Color. Dis. 29:3 (2014), 387–393.
13. Scheppach, W., Sommer, H., Kirchner, T., Paganelli, G.-M., Bartram, P., Christl, S., Richter, F., Dusel, G., Kasper, H., Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103:1 (1992), 51–56.
14. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. U. S. A. 111:6 (2014), 2247–2252.
15. Lee, C., Chun, J., Hwang, S.W., Kang, S.J., Im, J.P., Kim, J.S., The effect of intestinal alkaline phosphatase on intestinal epithelial cells, macrophages and chronic colitis in mice. Life Sci. 100:2 (2014), 118–124.
16. Seo, J.Y., Lee, C., Hwang, S.W., Chun, J., Im, J.P., Kim, J.S., Nimbolide inhibits nuclear factor-capital KA, CyrillicB pathway in intestinal epithelial cells and macrophages and alleviates experimental colitis in mice. Phytother. Res. 30:10 (2016), 1605–1614.
17. Lee, C., Chun, J., Hwang, S.W., Kang, S.J., Im, J.P., Kim, J.S., Enalapril inhibits nuclear factor-kappaB signaling in intestinal epithelial cells and peritoneal macrophages and attenuates experimental colitis in mice. Life Sci. 95:1 (2014), 29–39.
18. Chun, J., Lee, C., Hwang, S.W., Im, J.P., Kim, J.S., Ursolic acid inhibits nuclear factor-kappaB signaling in intestinal epithelial cells and macrophages, and attenuates experimental colitis in mice. Life Sci. 110:1 (2014), 23–34.
19. Kajiguchi, T., Yamamoto, K., Iida, S., Ueda, R., Emi, N., Naoe, T., Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 97:6 (2006), 540–545.
20. Kim, J., Kim, N., Park, J.H., Chang, H., Kim, J.Y., Lee, D.H., Kim, J.M., Kim, J.S., Jung, H.C., The effect of Helicobacter pylori on epidermal growth factor receptor-induced signal transduction and the preventive effect of celecoxib in gastric cancer cells. Gut and Liver 7:5 (2013), 552–559.
21. Lee, C., Lee, J.W., Seo, J.Y., Hwang, S.W., Im, J.P., Kim, J.S., Lupeol inhibits LPS-induced NF-kappa B signaling in intestinal epithelial cells and macrophages, and attenuates acute and chronic murine colitis. Life Sci. 146 (2016), 100–108.
22. Renard, P., Ernest, I., Houbion, A., Art, M., Le Calvez, H., Raes, M., Remacle, J., Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res., 29(4), 2001, E21.
23. Krieglstein, C.F., Cerwinka, W.H., Sprague, A.G., Laroux, F.S., Grisham, M.B., Koteliansky, V.E., Senninger, N., Granger, D.N., de Fougerolles, A.R., Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J. Clin. Invest. 110:12 (2002), 1773–1782.
24. Dieleman, L.A., Palmen, M.J., Akol, H., Bloemena, E., Pena, A.S., Meuwissen, S.G., Van Rees, E.P., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114:3 (1998), 385–391.
25. Berg, D.J., Zhang, J., Weinstock, J.V., Ismail, H.F., Earle, K.A., Alila, H., Pamukcu, R., Moore, S., Lynch, R.G., Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123:5 (2002), 1527–1542.
26. Zigmond, E., Bernshtein, B., Friedlander, G., Walker, Catherine R., Yona, S., Kim, K.-W., Brenner, O., Krauthgamer, R., Varol, C., Müller, W., Jung, S., Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40:5 (2014), 720–733.
27. SÄEMANN, M.D., BÖHMIG, G.A., ÖSTERREICHER, C.H., BURTSCHER, H., PAROLINI, O., DIAKOS, C., STÖCKL, J., HÖRL, W.H., ZLABINGER, G.J., Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 14:15 (2000), 2380–2382.
28. Krause, P., Morris, V., Greenbaum, J.A., Park, Y., Bjoerheden, U., Mikulski, Z., Muffley, T., Shui, J.W., Kim, G., Cheroutre, H., Liu, Y.C., Peters, B., Kronenberg, M., Murai, M., IL-10-producing intestinal macrophages prevent excessive antibacterial innate immunity by limiting IL-23 synthesis. Nat. Commun., 6, 2015, 7055.
29. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., Muller, W., Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:2 (1993), 263–274.
30. Kotlarz, D., Beier, R., Murugan, D., Diestelhorst, J., Jensen, O., Boztug, K., Pfeifer, D., Kreipe, H., Pfister, E.D., Baumann, U., Puchalka, J., Bohne, J., Egritas, O., Dalgic, B., Kolho, K.L., Sauerbrey, A., Buderus, S., Gungor, T., Enninger, A., Koda, Y.K., Guariso, G., Weiss, B., Corbacioglu, S., Socha, P., Uslu, N., Metin, A., Wahbeh, G.T., Husain, K., Ramadan, D., Al-Herz, W., Grimbacher, B., Sauer, M., Sykora, K.W., Koletzko, S., Klein, C., Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143:2 (2012), 347–355.
31. Lee, W.-J., Hase, K., Gut microbiota-generated metabolites in animal health and disease. Nat. Chem. Biol. 10:6 (2014), 416–424.
32. Wang, F., Liu, J., Wong, T., Shen, K., Chen, Z., Yu, Y., Huang, Q., Wang, G., Liu, Z., Jin, S., The inflammation induced by lipopolysaccharide can be mitigated by short chain fatty acid, butyrate, through up-regulation of IL-10 in septic shock. Scand. J. Immunol. 85:4 (2017), 258–263.
33. Tambuwala, M.M., Natural nuclear factor kappa beta inhibitors: safe therapeutic options for inflammatory bowel disease. Inflamm. Bowel Dis. 22:3 (2016), 719–723.
34. Adam, E., Quivy, V., Bex, F., Chariot, A., Collette, Y., Vanhulle, C., Schoonbroodt, S., Goffin, V., Nguyen, T.L., Gloire, G., Carrard, G., Friguet, B., De Launoit, Y., Burny, A., Bours, V., Piette, J., Van Lint, C., Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol. Cell. Biol. 23:17 (2003), 6200–6209.
35. Daniel, P., Brazier, M., Cerutti, I., Pieri, F., Tardivel, I., Desmet, G., Baillet, J., Chany, C., Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin. Chim. Acta 181:3 (1989), 255–263.
36. Zhang, T., Ding, C., Zhao, M., Dai, X., Yang, J., Li, Y., Gu, L., Wei, Y., Gong, J., Zhu, W., Li, N., Li, J., Sodium butyrate reduces colitogenic immunoglobulin A-coated bacteria and modifies the composition of microbiota in IL-10 deficient mice. Nutrients, 8(12), 2016.
37. Sueyoshi, R., Ignatoski, K.M., Daignault, S., Okawada, M., Teitelbaum, D.H., Angiotensin converting enzyme-inhibitor reduces colitis severity in an IL-10 knockout model. Dig. Dis. Sci. 58:11 (2013), 3165–3177.
38. Kang, S.J., Kim, J.M., Koh, S.J., Kim, S.H., Im, J.P., Jung, H.C., Kim, J.S., The guggulsterone derivative GG-52 inhibits NF-kappaB signaling in bone marrow-derived dendritic cells and attenuates colitis in IL-10 knockout mice. Life Sci. 92:22 (2013), 1064–1071.
39. Hamer, H.M., Jonkers, D.M., Vanhoutvin, S.A., Troost, F.J., Rijkers, G., de Bruine, A., Bast, A., Venema, K., Brummer, R.J., Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clinical Nutrition (Edinburgh, Scotland) 29:6 (2010), 738–744.
40. Luhrs, H., Gerke, T., Muller, J.G., Melcher, R., Schauber, J., Boxberge, F., Scheppach, W., Menzel, T., Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand. J. Gastroenterol. 37:4 (2002), 458–466.
41. Luceri, C., Femia, A.P., Fazi, M., Di Martino, C., Zolfanelli, F., Dolara, P., Tonelli, F., Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: a randomized trial. Dig. Liver Dis. 48:1 (2016), 27–33.
42. Steinhart, A.H., Hiruki, T., Brzezinski, A., Baker, J.P., Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment. Pharmacol. Ther. 10:5 (1996), 729–736.
43. Simeoli, R., Mattace Raso, G., Pirozzi, C., Lama, A., Santoro, A., Russo, R., Montero-Melendez, T., Berni Canani, R., Calignano, A., Perretti, M., Meli, R., An orally administered butyrate-releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium-induced murine colitis. Br. J. Pharmacol., 2016.
44. Eeckhaut, V., Machiels, K., Perrier, C., Romero, C., Maes, S., Flahou, B., Steppe, M., Haesebrouck, F., Sas, B., Ducatelle, R., Vermeire, S., Van Immerseel, F., Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut 62:12 (2013), 1745–1752.